NasdaqGS:RPRXPharmaceuticals
Does Royalty Pharma’s 41% Rally in 2025 Signal a Stronger Outlook?
If you are weighing whether to jump into Royalty Pharma or considering if it is time to take some profits, you are not alone. This stock has become a topic of lively debate, especially as its recent run has caught the attention of both cautious and opportunistic investors. Over the past year, Royalty Pharma has delivered a total return of over 34%. What really stands out is its nearly 41% surge year-to-date. While its five-year numbers are barely in the red, the short-term momentum is...